RNF152-mediated, ubiquitin-dependent degradation of HSP27 activates the PI3K/AKT pathway, driving synovial inflammatory cascades in TMJOA Authors: Xinjian Zhang, Qingkun Jiang, Wei Deng, Hai Tang, Yang Liu, Zichen Xu, Ke Guo, Ning Liu, Haitao Wang, Tiehan Cui, Fang Wang, Jiaxuan Qiu Published: 2025 ABSTRACT BackgroundE3 ubiquitin ligases are established regulators of osteoarthritis pathogenesis known to amplify inflammatory signals via substrate protein destabilization, but their role in temporomandibular joint osteoarthritis (TMJOA) remains elusive.MethodsThis study investigated the impact of E3 ligases on the activation of fibroblast-like synoviocytes (FLSs) in TMJOA and their mechanistic contributions to disease progression. High-throughput mRNA-sequencing identified dysregulated E3 ligases in interleukin-1β (IL-1β)–stimulated FLSs. Through integrated in vitro and in vivo analyses, we identified ring finger protein 152 (RNF152) as a key mediator of TMJOA pathogenesis. Comprehensive results from immunoprecipitation-mass spectrometry, co-immunoprecipitation, co-localization imaging, and protein docking demonstrated direct interaction between RNF152 and heat shock protein 27 (HSP27).ResultsIL-1β induced RNF152 upregulation while suppressing HSP27 expression in FLSs. Mechanistically, RNF152 ubiquitinated HSP27 at Lys114, making it a target for proteasomal degradation. Critically, RNF152-mediated HSP27 degradation activated the PI3K/AKT pathway, driving FLS proliferation and pro-inflammatory cytokine release, which accelerates TMJOA. Intra-articular delivery of adenovirus-associated virus-small interfering RNF152 attenuated synovial hyperplasia and chondrocyte damage in a rat model of TMJOA.ConclusionThis study elucidates the function of RNF152 as a novel E3 ligase and the dual regulatory role of HSP27 in inflammatory signaling. Importantly, our findings suggest that targeting the RNF152/HSP27/PI3K/AKT signaling axis may provide a novel therapeutic approach for TMJOA. Future research should focus on developing specific inhibitors to disrupt this pathway, thereby identifying promising therapeutic targets for targeted interventions in TMJOA.Supplementary InformationThe online version contains supplementary material available at 10.1186/s13075-025-03715-4. Introduction Temporomandibular joint osteoarthritis (TMJOA) is a prevalent chronic degenerative disorder characterized by progressive cartilage degradation, synovial inflammation, and subchondral bone remodeling. It can lead to significant functional impairment, including pain, limited jaw mobility, and crepitus [1]. The pathogenesis of TMJOA involves intricate interactions among various joint tissues, with synovial inflammation playing a pivotal role. Fibroblast-like synoviocytes (FLSs) are specialized mesenchymal cells that reside in the synovial membrane. Under normal conditions, FLSs maintain joint homeostasis by producing extracellular matrix components and secreting lubricating proteins [2]. However, in the context of TMJOA, improper activation leads to FLSs to produce pro-inflammatory cytokines, matrix metalloproteinases (MMPs), and extracellular vesicles, which collectively promote cartilage degradation and perpetuate synovitis [3]. This aberrant FLS activity disrupts the delicate balance between tissue repair and degradation, accelerating the degenerative process. The crosstalk between FLSs and other joint cells, such as chondrocytes and macrophages, can further amplify the inflammatory response and exacerbate tissue damage. Accordingly, precise targeting of the molecular pathways involved in FLS activation and synovial inflammation holds promise as an effective treatment strategy for TMJOA.​ Ubiquitination is a post-translational modification with critical regulatory roles in various cellular processes, including protein degradation, signal transduction, and inflammation, which are crucial in the pathogenesis of osteoarthritis (OA) [4]. Among the components of the ubiquitin-proteasome system, E3 ubiquitin ligases are pivotal in recognizing substrates and catalyzing the transfer of ubiquitin, thereby influencing protein turnover and cellular homeostasis [5]. Ring finger protein 152 (RNF152), a member of the Ring-type E3 ligase family, has been identified as a positive regulator of Toll-like receptor (TLR)/interleukin-1 receptor (IL-1R)–mediated signaling pathways. Prior research has demonstrated that RNF152-deficient mice produce fewer inflammatory cytokines in response to lipopolysaccharide (LPS) treatment and exhibit enhanced resistance to LPS-induced lethal endotoxemia [6]. Although RNF152 has been established as a modulator of inflammatory responses in conditions including OA, its potential involvement in the pathogenesis of TMJOA has yet to be systematically explored. During the progression of OA, IL-1β initiates a robust inflammatory response by activating a complex network of signaling pathways, and the PI3K/Akt pathway is intricately associated with IL-1β–induced inflammation [7]. Multiple studies have demonstrated that both PI3K and Akt are rapidly phosphorylated following stimulation with IL-1β [8]– [9]. Activation of PI3K and Akt signaling plays a crucial role in the phosphorylation and nuclear translocation of nuclear factor-kappa B (NF-κB) p65, thereby enhancing the production of inflammatory mediators [10]. Additionally, IL-1β and tumor necrosis factor alpha (TNF-α) have been shown to modulate the expression of PI3Kδ, promoting the proliferation and migration of FLSs, which contributes to cartilage degradation. Accordingly, targeting of PI3Kδ was found to reduce the inflammatory response in synoviocytes [11]. Moreover, inhibition of PI3Kγ reduces TNF-α–induced MMP expression and decreases Akt activation in synovial fibroblasts [12]. However, the synovial microenvironment is highly complex, and the precise mechanisms underlying the regulatory role of PI3K/Akt signaling in FLSs remain unclear, requiring further investigation. Heat shock protein 27 (HSP27) is a member of the small heat shock protein family, which consists of ubiquitously expressed molecular chaperones that maintain cellular proteostasis under stress conditions [13]. Prior studies in OA revealed downregulation of HSP27 in chondrocytes, where it plays a crucial role in maintaining articular chondrocyte homeostasis by regulating cellular metabolism and IL-1β–induced IL-6 secretion [14]– [15]. However, the role of HSP27 in modulating synovial inflammation in TMJOA has yet to be elucidated. In the present study, we investigated the role E3 ubiquitin ligases in the pathogenesis of TMJOA. We first established a TMJOA cell model by stimulating FLSs with IL-1β. Upon the identification of the E3 ubiquitin ligase RNF152 as dysregulated in this model, we explored its roles in regulating FLS proliferation, apoptosis, and inflammation. Our results indicate that RNF152 facilitates activation of the PI3K/Akt signaling pathway by mediating the ubiquitin-dependent degradation of HSP27, thereby influencing the pathogenesis and progression of TMJOA. Materials and methods Cell culture Normal human FLS (HFLS-N) (Cat#HTX2177,Male,24) and OA model HFLS (HFLS-OA) (Cat#HTX2092,Female,52) cells were purchased from Otwo Biotech Co., Ltd (Shenzhen, China). The cells were cultured in the complete medium (Pricella, Wuhan, China), including Dulbecco’s Modified Eagle Medium (DMEM)/Nutrient Mixture F-12 (DMEM/F12), Iscove’s Modified Dulbecco Medium, Roswell Park Memorial Institute 1640, and DMEM. Cells were grown in a humidified atmosphere with 5% CO2 at 37 °C. Transcriptome library preparation and RNA-sequencing and analysis For the IL-1β–stimulated group, FLSs were treated with 30 ng/mL recombinant human IL-1β (Novoprotein, Cat# P01584) for 24 h. Total RNA was subsequently extracted from nine independent samples (three biological replicates per group: FLS control, IL-1β–stimulated FLS, and FLS-OA) using TRIzol reagent (Invitrogen, Cat# 15596026CN) according to the manufacturer’s protocol. Clean reads were aligned to the reference genome (GRCh38.p13) using HISAT2 (v2.2.1) [16] to determine genomic positional information and sample-specific sequence features. Protein-coding gene expression abundance was quantified by mapping sequence reads to annotated reference gene sequences. Read counts per gene were generated using htseq-count (v0.13.5) [17]. Differential expression analysis was performed with DESeq2 (v1.30.1) [18] through: (a) count normalization (expression estimated via baseMean), (b) fold-change calculation, and (c) statistical testing using negative binomial generalized linear models. Differentially expressed protein-coding genes were identified based on threshold criteria of a |log₂(fold-change)| >1 and a false discovery rate (FDR) < 0.05.We have deposited the raw sequencing data in the National Center for Biotechnology Information (NCBI) BioProject database under accession number PRJNA1362948(https://dataview.ncbi.nlm.nih.gov/object/PRJNA1362948?reviewer=d807qkpgkbqv0pblvp89jj0iik). Cell transfection and inflammation induction The small interfering RNAs RNF152-siRNA-normal control (NC) and RNF152-siRNA were synthesized by RIB.BIO (Guangzhou, China). The HSP27-siRNA-NC and HSP27-siRNA were synthesized by Tsingke Biotechnology Co., Ltd. (Beijing, China). The following sequences were used:RNF152-siRNA-002–5’-CTTGCGTCTTGGTCTTCCT-3’,RNF152-siRNA-003–5’-GCATCGTGCTTCACAACAT-3’,HSP27-siRNA-NC-5’-UUCUCCGAACGUGUCACGU-3’, and HSP27-siRNA-002–5’-CCAUAGUUGAGCCCUGAUU-3’ RNF152-siRNA-002–5’-CTTGCGTCTTGGTCTTCCT-3’, RNF152-siRNA-002–5’-CTTGCGTCTTGGTCTTCCT-3’, RNF152-siRNA-003–5’-GCATCGTGCTTCACAACAT-3’, RNF152-siRNA-003–5’-GCATCGTGCTTCACAACAT-3’, HSP27-siRNA-NC-5’-UUCUCCGAACGUGUCACGU-3’, and HSP27-siRNA-002–5’-CCAUAGUUGAGCCCUGAUU-3’ HSP27-siRNA-NC-5’-UUCUCCGAACGUGUCACGU-3’, and HSP27-siRNA-002–5’-CCAUAGUUGAGCCCUGAUU-3’ RNF152 and HSP27 overexpression plasmids, along with corresponding empty vector controls, were procured from Miaoling Biology (Wuhan, China). Transient transfection was performed using Lipofectamine™ 3000 reagent (Invitrogen, Cat# L3000008) according to the manufacturer’s protocol. The siRNA transfection dose was 50 nM, and the dose of overexpression plasmids was 2 µg. After a 48-h transfection period, the TMJOA inflammation model was stimulated by addition of 30 ng/mL recombinant human IL-1β (Novoprotein, Cat# P01584) for 24 h. Edu assay The EdU (5-ethynyl-2’-deoxyuridine) labeling and detection kit (C6045M) was procured from UElandy (Suzhou, China). Cells were placed in wells of 96-well plates at 5 × 10³cells/well and cultured to 60–70% confluency. A 10 mM EdU stock solution was diluted to 20 µM in complete growth medium, and 100 µL of this working solution was added per well. After incubation for 3 h at 37 °C under 5% CO₂, the culture medium was aspirated, and cells were washed twice with 1X phosphate-buffered saline (PBS) for 5 min per wash to remove unincorporated EdU. Subsequently, 50 µL of 4% paraformaldehyde fixative was added per well for incubation for 20 min at room temperature (RT). After fixation, cells were treated with 50 µL of 2 mg/mL glycine solution (5 min, RT) to neutralize residual fixative. Following two washes with 100 µL of 3% bovine serum albumin (BSA)/PBS, permeabilization was performed using 100 µL of 0.5% Triton X-100 (30 min, RT). The EdU detection cocktail was then prepared according to manufacturer’s instructions, applied (100 µL/well), and incubated for 30 min under light-protected conditions. After two additional washes with 3% BSA/PBS, nuclei were counterstained with 100 µL of 1X Hoechst 33,342 solution (15 min, RT, light-protected). Finally, cells underwent two PBS washes before imaging and analysis. Apoptosis assay Apoptosis among FLSs was assessed using a FITC Annexin V/PI Apoptosis Detection Kit (UElandy, Suzhou, China). Following transfection, cells were harvested by trypsinization, washed twice with ice-cold PBS, and resuspended in 100 µL of binding buffer. Subsequently, 5µL of fluorescein isothiocyanate (FITC)-conjugated Annexin V and 5 µL of propidium iodide (PI) were added to each sample with gentle vortexing. After 15 min of incubation at RT under light-protected conditions, 400 µL of binding buffer was added prior to flow cytometric analysis. Enzyme-linked Immunosorbent Assay (ELISA) Concentrations of IL-6, IL-8, and TNF-α in cell culture supernatant samples were quantified using commercial ELISA kits (Invitrogen, USA) according to the manufacturer’s protocols. Reverse transcription quantitative polymerase chain reaction (RT-qPCR) Total RNA was extracted using the EZ-press™ RNA Purification Kit PLUS (EZBioscience, Cat# B0004-PLUS). Complementary DNA (cDNA) synthesis was performed with FastKing gDNA Dispelling RT SuperMix (TIANGEN BIOTECH, Beijing) according to the manufacturer’s protocol. Quantitative real-time PCR (qPCR) analysis employed FastReal qPCR PreMix (SYBR Green; TIANGEN) on a Bio-Rad CFX96 system under the following thermal profile: initial denaturation at 95 °C for 2 min and 40 cycles of 95 °C for 5 s and 60 °C for 15 s. Relative mRNA expression levels were calculated using the 2^−ΔΔCt method, with the primer sequences listed in Supplementary Table 1. Western blotting Whole-cell protein lysates were prepared using radioimmunoprecipitation assay (RIPA) buffer supplemented with protease and phosphatase inhibitors. Protein concentrations were quantified via BCA assay (Servicebio, Cat# G2026-1000T). Equivalent protein aliquots were denatured in loading buffer at 95 °C for 10 min. Electrophoretic separation was performed on 10% sodium dodecyl sulfate (SDS)-polyacrylamide gels (80 V for 15 min; 120 V for 60 min), followed by polyvinylidene difluoride (PVDF) membrane transfer (300 mA, 60 min, ice bath). Membranes were briefly rinsed in Tris-buffered saline with Tween 20 (TBST) and inactivated in the blocking solution at 4 °C for 30 min before incubation overnight at 4 °C with the following primary antibodies: anti-RNF152 (sc-398391, Santa Cruz Biotechnology), anti-HSP27 (18284-1-AP, Proteintech), anti-Flag (ab205606, Abcam), anti-Myc (YM3002, ImmunoWay), anti-Bax (50599-2-Ig, Proteintech), anti-Bcl-2 (12789-1-AP, Proteintech), anti-cleaved caspase-3 (25128-1-AP, Proteintech), anti-AKT (10176-2-AP, Proteintech), anti-phospho-AKT (Ser473) (66444-1-Ig, Proteintech), anti-PI3K (60225-1-Ig, Proteintech), and anti-phospho-PI3K p85 (Tyr458) (AF3242, Affinity Biosciences). After TBST washes, membranes were incubated with species-matched horseradish peroxidase (HRP)-conjugated secondary antibodies (1:5000) for 60 min at 4 °C. Protein bands were visualized using an enhanced chemiluminescence (ECL) detection kit (Servicebio, Cat# G2020-50ML) and quantified densitometrically with ImageJ software (NIH). β-tubulin was used as the internal control. Co-immunoprecipitation (Co-IP) and ubiquitination assay Co-IP was performed to assess the RNF152–HSP27 interaction in FLSs using antibodies against RNF152 (sc-398391, Santa Cruz Biotechnology), HSP27 (18284-1-AP, Proteintech), Flag (ab205606, Abcam), Myc (YM3002, ImmunoWay), and immunoglobulin G (IgG) control (30000-0-AP, Proteintech). Whole-cell lysates were centrifuged at 12,000 rpm for 15 min at 4 °C, and supernatant samples were incubated with 1 µg of respective antibodies overnight at 4 °C on a rotary mixer. Pre-washed Protein A/G magnetic beads (MedChemExpress, HY-K0202) were then added to the complexes and incubated for 4 h at 4 °C with rotation. After magnetic separation, beads underwent three washes with IP buffer, followed by elution in 25 µL 1× SDS-polyacrylamide gel electrophoresis (PAGE) loading buffer at 95 °C for 10 min. Eluates were collected for immunoblotting after final magnetic separation. The level of ubiquitinated HSP27 in the immune complexes was evaluated using anti-ubiquitin antibody (10201-2-AP, Proteintech). TMJOA animal model Twenty-four 7-week-old female Spraque–Dawley rats (160–180 g) from CSTQSW (Changsha, China) were used to generate the experimental TMJOA model via unilateral anterior crossbite (UAC) surgery [19]. After 1 week of acclimatization, anesthesia was administered using 2–4% isoflurane in oxygen, the rats were immobilized on the surgical platform, whereupon custom UAC appliances fabricated from bovine teat cannulas were cemented to the left maxillary and mandibular incisors with zinc phosphate cement. At 1 month post-UAC, the surgical site (temporomandibular joint area) underwent hair removal followed by thorough disinfection with 75% alcohol. AAV-injected groups received intra-articular TMJ injections of either AAV-siRNF152 (1.05 × 10¹³ vg in 12.5 µL) or vector control (1.0 × 10¹² vg in 2 µL), while control and TMJOA groups received equivalent saline volumes. Four weeks later, micro-computed tomography (CT) analysis was performed for osseous assessment. Subsequently, in vivo bioluminescence imaging was conducted upon intraperitoneal injection of D-luciferin potassium salt (15 mg/mL). After this analysis, the rats were euthanized via chloral hydrate overdose, and the TMJs were harvested and stored at − 80 °C until further analysis. All surgical procedures were performed under aseptic conditions. All surgical manipulations were carried out by researchers wearing sterile surgical gloves. All procedures involving animals were approved by the Animal Ethics Committee of the First Affiliated Hospital of Nanchang University (Approval #CDYFY-IACUC-202407QR220). Histological analysis, scoring system, and immunohistochemistry The harvested TMJs were fixed in 10% neutral-buffered formalin and decalcified in 5% formic acid-hydrochloric acid solution. After dehydration through submersion in a graded ethanol series, tissues were paraffin-embedded and sectioned at 5-µm thickness for staining with hematoxylin and eosin (H&E) or Safranin O-fast green. The severity of synovitis and cartilage degeneration was evaluated using the Synovitis and Osteoarthritis Research Society International (OARSI) grading systems by two blinded investigators [20]– [21]. For immunohistochemistry, deparaffinized and rehydrated sections were immunostained with antibodies against collagen 2A1 (COL2A1, 1:800, Proteintech 28459-1-AP), MMP13 (1:200, Proteintech 18165-1-AP), and IL-6 (1:100, Affinity Biosciences DF6087) according to manufacturer’s protocols with appropriate antigen retrieval. Positively stained cells within the mandibular condylar and synovium region were quantified using Image-Pro Plus 6.0 software (Media Cybernetics, Inc., Rockville, MD, USA), with the results expressed as the percentage of positively stained cells. Statistical analysis All data are expressed as mean ± Standard Error of Mean (mean ± SEM). Statistical analyses were performed using GraphPad Prism 9.0 (GraphPad Software, San Diego, CA). Between-group comparisons were made using Student’s t-test, one-way analysis of variance (ANOVA) with Tukey’s post hoc test, or Mann–Whitney U test as appropriate. Statistical significance was defined as P < 0.05. Results RNF152 expression is elevated in IL-1β–stimulated FLSs, FLSs-OA, and synovial tissues of TMJOA model rats To identify potential E3 ubiquitin ligases involved in the pathogenesis of TMJOA, we conducted second-generation transcriptomic sequencing on FLSs, IL-1β–stimulated FLSs, and FLSs-OA.Differential expression analysis identified 1,651 up- and 1,105 down-regulated genes between FLSs-OA and FLSs; 622 up- and 283 down-regulated with IL-1β stimulation versus control; and 1,184 up- and 1,546 down-regulated in FLSs-OA versus IL-1β–stimulated FLSs(Supplementary Fig. 1A).This analysis identified 502 differentially expressed genes (Supplementary Fig. 1B). These genes were compared with the human E3 ubiquitin ligase dataset, sourced from several databases including the Cell Signaling Database, the hUbiqutome Database, Qiagen Ubiquitin Ligases PCR Array, UbiProt Database, and Dude v. 1.0. The results indicated a significant association with human E3 ubiquitin ligases, revealing six differentially expressed E3 ubiquitin ligase genes: RNF152, LONRF2, HERC5, RNF150, TRIM36, and BIRC3 (Supplementary Fig. 1C). Both HERC5 [22] and BIRC3 [23] were identified in our RNA-sequencing analysis, confirming the reliability of our experimental system. To further validate these findings, we performed qPCR analysis of these six genes (Supplementary Fig. 1D). RNF152 was notably upregulated in IL-1β–stimulated FLSs and FLSs-OA (Fig. 1A and B). Given the unknown role of RNF152 in TMJOA, we proceeded to further investigate its function. First, we analyzed the expression of RNF152 protein in Il-1β–stimulated FLSs and FLSs-OA and observed significantly higher levels of RNF152 protein in FLSs-OA than in normal FLSs (Fig. 1C-D). Additionally, we evaluated RNF152 expression in TMJOA through immunohistochemical analysis of synovial tissues from rats with UAC-induced TMJOA. The staining results demonstrated elevated RNF152 expression in the UAC-induced TMJOA synovial tissues (Fig. 1E-F). Fig. 1RNF152 expression was elevated in IL-1β–stimulated FLSs, FLSs-OA, and synovial tissues of TMJOA model rats. A, Heatmap visualization of differentially expressed genes between normal FLSs, IL-1β–stimulated FLSs, and FLSs-OA. B, qPCR analysis confirmed significant upregulation of RNF152 in IL-1β–stimulated FLSs and FLSs-OA. C, Western blot analysis confirmed significantly elevated RNF152 protein expression in IL-1β–stimulated FLSs and FLSs-OA. D, Quantification of RNF152 protein expression in (C) using ImageJ. E, Representative images of RNF152 immunostaining in synovial tissues of rat TMJs: normal vs. TMJOA (n = 6). F, Comparison of the percentage of RNF152-positive cells in synovial tissue samples from rat TMJs (samples are shown in E). n indicates the number of biologically independent samples.Scale bars = 50 μm. Data are presented as mean ± SEM. Statistical significance was determined using an unpaired t-test and ordinary one-way ANOVA.***P < 0.001, ****P < 0.0001 RNF152 expression was elevated in IL-1β–stimulated FLSs, FLSs-OA, and synovial tissues of TMJOA model rats. A, Heatmap visualization of differentially expressed genes between normal FLSs, IL-1β–stimulated FLSs, and FLSs-OA. B, qPCR analysis confirmed significant upregulation of RNF152 in IL-1β–stimulated FLSs and FLSs-OA. C, Western blot analysis confirmed significantly elevated RNF152 protein expression in IL-1β–stimulated FLSs and FLSs-OA. D, Quantification of RNF152 protein expression in (C) using ImageJ. E, Representative images of RNF152 immunostaining in synovial tissues of rat TMJs: normal vs. TMJOA (n = 6). F, Comparison of the percentage of RNF152-positive cells in synovial tissue samples from rat TMJs (samples are shown in E). n indicates the number of biologically independent samples.Scale bars = 50 μm. Data are presented as mean ± SEM. Statistical significance was determined using an unpaired t-test and ordinary one-way ANOVA.***P < 0.001, ****P < 0.0001 Silencing of RNF152 inhibits IL-1β–induced proliferation and inflammation of FLSs, while promoting their apoptosis To investigate the role of RNF152 in TMJOA, FLSs were transfected with either RNF152 siRNA-NC or RNF152-specific siRNA and subsequently stimulated with IL-1β (Supplementary Fig. 2A). The most effective silencing was achieved using the siRNF152-002 and siRNF152-003 constructs, which were selected for use in subsequent experiments. qPCR analysis indicated that the expression levels of inflammatory factors IL-6, IL-8, and TNF-α decreased after silencing of RNF152 in FLSs (Supplementary Fig. 2B-C). Western blot analysis confirmed successful knockdown of RNF152 by both siRNF152-002 and siRNF152-003 (Fig. 2A-B). EdU and flow cytometric assays demonstrated that silencing RNF152 in FLSs effectively reversed the IL-1β–induced increase in cell proliferation and decrease in apoptosis (Fig. 2C-F). Western blot results further revealed that RNF152 silencing upregulated the expression of pro-apoptotic proteins Bax and cleaved caspase-3, while downregulating the anti-apoptotic protein Bcl-2 (Fig. 2G-H). Additionally, ELISA results showed that IL-1β stimulation of FLSs significantly increased the concentrations of IL-6, IL-8 and TNF-α, which were reduced by RNF152 silencing in FLSs (Fig. 2I-K). Fig. 2Silencing of RNF152 inhibited IL-1β–induced proliferation and inflammation of FLSs, while promoting their apoptosis. A, Western blot analysis confirmed RNF152 protein silencing in FLSs after treatment with siRNF152-002 and siRNF152-003. B, Quantification of protein expression results in (A) using ImageJ. C-F, EdU assay and flow cytometric analysis of FLS proliferation and apoptosis. G, Western blot analysis of apoptosis-related protein expression. H, Quantification of protein expression results in (G). I-K, Levels of pro-inflammatory factors in cell culture supernatant by ELISA.Scale bars = 100 μm.Data are presented as mean ± SEM. Statistical significance was determined using ordinary one-way ANOVA. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 Silencing of RNF152 inhibited IL-1β–induced proliferation and inflammation of FLSs, while promoting their apoptosis. A, Western blot analysis confirmed RNF152 protein silencing in FLSs after treatment with siRNF152-002 and siRNF152-003. B, Quantification of protein expression results in (A) using ImageJ. C-F, EdU assay and flow cytometric analysis of FLS proliferation and apoptosis. G, Western blot analysis of apoptosis-related protein expression. H, Quantification of protein expression results in (G). I-K, Levels of pro-inflammatory factors in cell culture supernatant by ELISA.Scale bars = 100 μm.Data are presented as mean ± SEM. Statistical significance was determined using ordinary one-way ANOVA. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 RNF152 interacts directly with HSP27 To investigate the mechanism of action by which RNF152 contributes to the pathogenesis of TMJOA, we performed an initial screening for substrate proteins that interact with RNF152. Through a combination of IP and MS experiments (Supplementary Fig. 3A), we identified 568 potential RNF152-binding proteins. Cross referencing of these proteins against the TMJOA database identified 17 candidate TMJOA-associated RNF152-binding proteins (Supplementary Fig. 3B-C), including HSP27. To confirm the interaction between RNF152 and HSP27, we first detected HSP27 in RNF152 immunoprecipitate samples using silver staining (Fig. 3A). Subsequent Co-IP experiments further validated the interaction between RNF152 and HSP27 (Fig. 3B-C). Consistent with these findings, we also observed an exogenous interaction between RNF152 and HSP27 (Fig. 3D-E). Immunofluorescence colocalization and molecular docking prediction models also supported direct interaction between these two proteins (Fig. 3F-H). Fig. 3RNF152 was found to interact directly with HSP27. A, Detection of RNF152 immunoprecipitates by silver staining and IP-MS analyses. B and C, Endogenous binding between RNF152 and HSP27, as validated by Co-IP. D and E, Exogenous Co-IP assays also validated RNF152–HSP27 binding. For these assays, 293 T cells were transfected with either Flag-tagged RNF152 or Myc-tagged HSP27 expression plasmids. IP was subsequently conducted using anti-Flag or anti-Myc antibodies, followed by immunoblotting with respective antibodies. F, Colocalization of RNF152 and HSP27 in FLSs (n = 3 per group).Scale bars = 25 μm. G, Co-localization scatter plot analysis revealed a Pearson’s correlation coefficient of 0.62 (indicating co-localization; range: 0.5–1.0). H, Molecular docking between RNF152 and HSP27 RNF152 was found to interact directly with HSP27. A, Detection of RNF152 immunoprecipitates by silver staining and IP-MS analyses. B and C, Endogenous binding between RNF152 and HSP27, as validated by Co-IP. D and E, Exogenous Co-IP assays also validated RNF152–HSP27 binding. For these assays, 293 T cells were transfected with either Flag-tagged RNF152 or Myc-tagged HSP27 expression plasmids. IP was subsequently conducted using anti-Flag or anti-Myc antibodies, followed by immunoblotting with respective antibodies. F, Colocalization of RNF152 and HSP27 in FLSs (n = 3 per group).Scale bars = 25 μm. G, Co-localization scatter plot analysis revealed a Pearson’s correlation coefficient of 0.62 (indicating co-localization; range: 0.5–1.0). H, Molecular docking between RNF152 and HSP27 RNF152 mediates HSP27 degradation via the proteasomal pathway by ubiquitinating HSP27 at K114 To investigate the regulatory effect of RNF152 on HSP27, we transfected FLSs with siRNF152-002 and siRNF152-003 before stimulation with IL-1β. Subsequently, we assessed the mRNA and protein levels of HSP27. The results revealed that silencing of RNF152 led to an increase in HSP27 protein expression in FLSs compared with the control group (Fig. 4B-C), without affecting HSP27 mRNA expression (Fig. 4A). In contrast, overexpression of RNF152 reduced HSP27 expression in a dose-dependent manner (Fig. 4D-E). Given that RNF152 is an E3 ubiquitin ligase, we examined the impact of RNF152 on HSP27 ubiquitination. Silencing of RNF152 resulted in a decrease in HSP27 ubiquitination (Fig. 4F), whereas RNF152 overexpression increased HSP27 ubiquitination (Fig. 4G). Moreover, after treatment of RNF152-overexpressing FLSs with the proteasome inhibitor MG132, the decreased HSP27 expression was restored in the control group with dimethyl sulfoxide (DMSO) addition in comparison with the control group (Fig. 4H). Consistently, after proteasome inhibition, the increased HSP27 expression caused by RNF152 silencing was abolished (Fig. 4I). These findings suggest that RNF152 regulates HSP27 degradation via the ubiquitin-proteasome system, which is dependent on the E3 ubiquitin ligase activity of RNF152. To identify the ubiquitination site on HSP27 targeted by RNF152, we utilized the ubiquitination site prediction website (https://www.phosphosite.org/) in conjunction with functional domain analysis of HSP27 (by InterProScan) to predict four potential ubiquitination sites: K112, K114, K123, and K171 (Supplementary Fig. 4A-B). IP assays revealed that overexpression of RNF152 did not increase ubiquitination of the HSP27 K114A mutant, indicating that K114 is a potential ubiquitination site on HSP27 (Fig. 4J). Subsequently, we examined whether RNF152 regulates the degradation of HSP27 through K114 ubiquitination. Silencing of RNF152 extended the half-life of wild-type (WT) HSP27 but did not affect the half-life of the HSP27 K114A mutant (Fig. 4K-L). Additionally, compared with WT HSP27, the HSP27 K114A mutant exhibited higher expression and no longer responded to RNF152 silencing (Fig. 4K-L), suggesting that RNF152 plays a regulatory role in the stability of HSP27 degradation. Fig. 4RNF152 was found to mediate HSP27 degradation via the proteasomal pathway by ubiquitinating HSP27 at K114. A, HSP27 mRNA levels in FLSs after the indicated treatments. B, Silencing of RNF152 resulted in increased HSP27 protein expression. C, Quantification of protein expression results in (B) using ImageJ. D, Representative immunoblot of HSP27 expression in FLSs transfected with the indicated RNF152 plasmids. E, Statistical analysis of the fold change in HSP27 expression in (D) (n = 3 independent experiments). F and G, IP with anti-HSP27 and western blotting with anti-ubiquitin (anti-Ub) in cells transfected with the different siRNAs targeting RNF152 for 24 h or RNF152 plasmids for 48 h. H and I, Immunoblots for the indicated proteins in FLSs transfected with the different RNF152 plasmids for 48 h (H) or siRNAs for 24 h (I), with or without MG132 treatment for 8 h. J, IP assays showed that RNF152 overexpression did not increase ubiquitination of the HSP27-K114A mutant. K, Representative immunoblots of HSP27 expression in FLSs with or without cycloheximide (CHX) treatment for the indicated times. L, Statistical analysis of HSP27 expression in samples treated as described in (K) (n = 3 independent experiments). ns, not significantly different.Data are presented as mean ± SEM. Statistical significance was determined using ordinary one-way ANOVA. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 RNF152 was found to mediate HSP27 degradation via the proteasomal pathway by ubiquitinating HSP27 at K114. A, HSP27 mRNA levels in FLSs after the indicated treatments. B, Silencing of RNF152 resulted in increased HSP27 protein expression. C, Quantification of protein expression results in (B) using ImageJ. D, Representative immunoblot of HSP27 expression in FLSs transfected with the indicated RNF152 plasmids. E, Statistical analysis of the fold change in HSP27 expression in (D) (n = 3 independent experiments). F and G, IP with anti-HSP27 and western blotting with anti-ubiquitin (anti-Ub) in cells transfected with the different siRNAs targeting RNF152 for 24 h or RNF152 plasmids for 48 h. H and I, Immunoblots for the indicated proteins in FLSs transfected with the different RNF152 plasmids for 48 h (H) or siRNAs for 24 h (I), with or without MG132 treatment for 8 h. J, IP assays showed that RNF152 overexpression did not increase ubiquitination of the HSP27-K114A mutant. K, Representative immunoblots of HSP27 expression in FLSs with or without cycloheximide (CHX) treatment for the indicated times. L, Statistical analysis of HSP27 expression in samples treated as described in (K) (n = 3 independent experiments). ns, not significantly different.Data are presented as mean ± SEM. Statistical significance was determined using ordinary one-way ANOVA. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 Overexpression of HSP27 inhibits IL-1β–induced proliferation and inflammation of FLSs, while promoting their apoptosis To investigate the role of HSP27 in TMJOA, we first examined the expression of HSP27 and found that, compared with those in normal FLSs, the mRNA and protein levels of HSP27 were downregulated in IL-1β–stimulated FLSs (Fig. 5A-C). Additionally, we performed immunohistochemical analysis of HSP27 in the synovial tissues of UAC-induced TMJOA rats. The results revealed a decrease in HSP27 expression in the synovial tissues of the TMJOA group compared with normal rats(Fig. 5D-E).We then overexpressed HSP27 in FLSs and stimulated them with IL-1β. Compared with the blank vector-transfected group, the FLSs with HSP27 overexpression did not exhibit IL-1β–induced downregulation of HSP27 (Fig. 5F-H). Moreover, EdU and flow cytometric assays indicated that overexpression of HSP27 effectively reversed the IL-1β–induced increase in cell proliferation and decrease in apoptosis (Fig. 5I-L). Western blot analysis further demonstrated that HSP27 overexpression led to upregulation of the pro-apoptotic proteins Bax and cleaved caspase-3 along with downregulation of the anti-apoptotic protein Bcl-2 (Fig. 5M-N). Additionally, qPCR and ELISA results revealed that IL-1β stimulation led to significant upregulation of IL-6, IL-8, and TNF-α, and these effects were reversed by overexpression of HSP27 (Fig. 5O-Q and Supplementary Fig. 4C). Fig. 5Overexpression of HSP27 inhibited IL-1β–induced proliferation and inflammation of FLSs, while promoting their apoptosis. A and B, Combined qPCR and immunoblot analyses confirmed downregulation of HSP27 in IL-1β–stimulated FLSs. C, Quantification of protein expression in (B) using ImageJ.D, Comparison of the percentage of HSP27-positive cells in synovial tissue samples from rat TMJs (samples are shown in E).E, Representative images of HSP27 immunostaining in synovial tissues of rat TMJs: normal vs. TMJOA (n = 3). F and G, qPCR and immunoblotting results for mRNA and protein expression of HSP27 in FLSs transfected with either HSP27 overexpression plasmid or empty vector control, followed by 24-hour stimulation with 30 ng/mL IL-1β. H, Quantification of protein expression in (E). I-L, EdU and flow cytometric assays of FLS proliferation and apoptosis after the indicated treatments. M, Western blot detection of the protein levels of apoptosis-related proteins. N, Quantification of protein expression in (K). O-Q, ELISA results for pro-inflammatory factor concentrations in the cell culture supernatant. ns, not significantly different.Scale bars = 50 μm.Data are presented as mean ± SEM. Statistical significance was determined using an unpaired t-tes, Two-way ANOVA and ordinary one-way ANOVA. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 Overexpression of HSP27 inhibited IL-1β–induced proliferation and inflammation of FLSs, while promoting their apoptosis. A and B, Combined qPCR and immunoblot analyses confirmed downregulation of HSP27 in IL-1β–stimulated FLSs. C, Quantification of protein expression in (B) using ImageJ.D, Comparison of the percentage of HSP27-positive cells in synovial tissue samples from rat TMJs (samples are shown in E).E, Representative images of HSP27 immunostaining in synovial tissues of rat TMJs: normal vs. TMJOA (n = 3). F and G, qPCR and immunoblotting results for mRNA and protein expression of HSP27 in FLSs transfected with either HSP27 overexpression plasmid or empty vector control, followed by 24-hour stimulation with 30 ng/mL IL-1β. H, Quantification of protein expression in (E). I-L, EdU and flow cytometric assays of FLS proliferation and apoptosis after the indicated treatments. M, Western blot detection of the protein levels of apoptosis-related proteins. N, Quantification of protein expression in (K). O-Q, ELISA results for pro-inflammatory factor concentrations in the cell culture supernatant. ns, not significantly different.Scale bars = 50 μm.Data are presented as mean ± SEM. Statistical significance was determined using an unpaired t-tes, Two-way ANOVA and ordinary one-way ANOVA. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 RNF152 activates the PI3K/AKT pathway by mediating HSP27 degradation, thereby regulating proliferation, apoptosis, and inflammation in IL-1β–stimulated FLSs Through a combination of immunoprecipitation and mass spectrometry (IP–MS) experiments, we identified 568 potential RNF152-binding proteins. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis revealed that these proteins were significantly enriched in the PI3K/AKT signaling pathway.(Fig. 6A).Existing studies have shown that HSP27, as an anti-inflammatory factor, plays a crucial defensive role in regulating inflammatory signaling pathways[24]. In certain inflammatory models, HSP27 was found to regulate the PI3K/AKT pathway through a negative feedback mechanism to mitigate excessive inflammatory responses[25]. Therefore, we examined the expression of proteins associated with the PI3K/AKT pathway. Western blot analysis revealed that in IL-1β–stimulated FLSs, the expression of phosphorylated (p)-PI3K and p-AKT was increased, while the expression of HSP27 was suppressed (Fig. 6B-C). To further investigate the impact of RNF152-mediated HSP27 ubiquitination on FLSs, we transfected FSLs with HSP27 siRNA-NC or HSP27-specific siRNA before IL-1β stimulation. The most effective silencing was achieved using the siHSP27-002 construct, which was then used for subsequent experiments (Supplementary Fig. 4D-E). FLSs were then transfected with the RNF152 overexpression plasmid or siRNF152 siRNA, or co-transfected with the RNF152 overexpression plasmid and HSP27 overexpression plasmid or RNF152 siRNA and HSP27 siRNA, followed by treatment with IL-1β. Western blot results indicated that HSP27 expression was increased and p-PI3K and p-AKT expression levels were reduced in the cells overexpressing both RNF152 and HSP27, as opposed to those overexpressing only RNF152. In FLSs in which both RNF152 and HSP27 were silenced, HSP27 expression was decreased, while the p-PI3K and p-AKT expression levels were higher than those in the cells with only RNF152 silencing (Fig. 6D-E). Additionally, EdU and flow cytometric assays demonstrated that HSP27 reversed the effects of RNF152 of FLS proliferation and apoptosis (Fig. 6H-K). qPCR, western blotting, and ELISA results further indicated that HSP27 reversed the effects of RNF152 on the expression of apoptosis-related proteins Bax, Bcl-2, cleaved caspase-3 and the release of pro-inflammatory factors (Fig. 6F-G, L-N and Supplementary Fig. 4F). Fig. 6RNF152 was found to activate the PI3K/AKT pathway by mediating HSP27 degradation, thereby regulating proliferation, apoptosis, and inflammation in IL-1β–stimulated FLSs. A,Enrichment analysis of differential proteins using the Kyoto Encyclopedia of Genes and Genomes (KEGG).B, Immunoblot analysis of the expression levels of HSP27 and PI3K/AKT pathway components in FLSs with or without IL-1β stimulation. C, Quantification of protein expression in (B) using ImageJ.D, Immunoblot analysis of protein expression of HSP27 and PI3K/AKT pathway components in IL-1β–stimulated FLSs with RNF152 or HSP27 silencing or overexpression. E, Quantification of protein expression in (D). F, Western blot detection of the protein levels of apoptosis-related proteins in FLSs after the indicated treatments. J, Quantification of protein expression in (F).H-K, FLS proliferation and apoptosis after the indicated treatments by EdU assay and flow cytometry, respectively. L-N, ELISA of pro-inflammatory factor levels in supernatant samples from FLSs after the indicated treatments. Scale bars = 50 μm.Data are presented as mean ± SEM. Statistical significance was determined using Two-way ANOVA and ordinary one-way ANOVA.*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 RNF152 was found to activate the PI3K/AKT pathway by mediating HSP27 degradation, thereby regulating proliferation, apoptosis, and inflammation in IL-1β–stimulated FLSs. A,Enrichment analysis of differential proteins using the Kyoto Encyclopedia of Genes and Genomes (KEGG).B, Immunoblot analysis of the expression levels of HSP27 and PI3K/AKT pathway components in FLSs with or without IL-1β stimulation. C, Quantification of protein expression in (B) using ImageJ.D, Immunoblot analysis of protein expression of HSP27 and PI3K/AKT pathway components in IL-1β–stimulated FLSs with RNF152 or HSP27 silencing or overexpression. E, Quantification of protein expression in (D). F, Western blot detection of the protein levels of apoptosis-related proteins in FLSs after the indicated treatments. J, Quantification of protein expression in (F).H-K, FLS proliferation and apoptosis after the indicated treatments by EdU assay and flow cytometry, respectively. L-N, ELISA of pro-inflammatory factor levels in supernatant samples from FLSs after the indicated treatments. Scale bars = 50 μm.Data are presented as mean ± SEM. Statistical significance was determined using Two-way ANOVA and ordinary one-way ANOVA.*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 RNF152 Silencing in the TMJ alleviates TMJOA progression in rats To further determine the role of RNF152 in the progression of TMJOA, we established a UAC-induced TMJOA model in rats. Successful modeling was confirmed through micro-CT bone analysis, HE staining, and Safranin O-fast green staining (Supplementary Fig. 5A-D). Next, we injected RNF152-silencing or control AAV vectors into the TMJ cavities of the rats (Fig. 7A and Supplementary Fig. 5E). In vivo imaging results revealed that AAV was concentrated in the TMJ region of these rats (Fig. 7B). CT scanning data of the TMJ were reconstructed in three dimensions using Imalytics Preclinical 3.1 software, and the bone analysis was localized to the condylar process of the TMJ (Fig. 7C). The UAC + AAV-siRNF152–treated group showed improvements in bone volume fraction (bone volume [BV]/trabecular volume [TV]), bone surface area to trabecular volume ratio (BS/BV), trabecular thickness (Tb.Th), trabecular separation (Tb.Sp), and bone mineral density (BMD) compared with the UAC + AAV-control–treated group (Fig. 7D-H). HE staining revealed synovial hyperplasia, vascular dilation, fibrin deposition, and angiogenesis with increased inflammatory cell infiltration in the UAC- and UAC + AAV-control- treated groups. However, after AAV-siRNF152 treatment, synovial hyperplasia was alleviated, and the synovial tissue score decreased. Similarly, Safranin O-fast green staining showed that compared with the control group, AAV-siRNF152 treatment led to an increase in condylar cartilage thickness, chondrocyte density, and recovery of proteoglycan (red regions) in the cartilage matrix, with a significant increase in the OARSI score (Fig. 7I-K). Furthermore, Immunohistochemical staining showed that in UAC-treated cartilage, COL2A1 expression was downregulated while MMP13 expression was upregulated. Additionally, IL-6 expression was elevated in the synovium.These changes were reversed by AAV-siRNF152 treatment (Fig. 7L-O). Together, these results suggest that RNF152 silencing alleviates the progression of TMJOA in rats. Fig. 7RNF152 silencing alleviated TMJOA progression in model rats. A, Schematic of experimental design: TMJOA model rats were treated with intra-articular injections of RNF152-silencing AAV or control AAV vectors and evaluated at 16 weeks of age. B, In vivo imaging of rats at 1-month post-AAV injection. C, Spatial localization of the mandibular condyles of rat TMJs utilizing Imalytics Preclinical 3.1 software during micro-CT analysis. D-H, Analysis of BV/TV ratio, BS/BV ratio, Tb.Th, Tb.Sp, and BMD (n = 6 per group). I, Representative images of HE and Safranin O-fast green staining of the synovium and chondrocytes.Scale bars = 50 μm. J and K, Quantification of synovitis and OARSI grading systems based on staining results in (I) (n = 6 per group). L, Representative images of immunohistochemical staining for IL-6, COL2A1, and MMP13 in the synovium and chondrocytes.Scale bars = 20 μm. M-O, Quantification of IL-6–, COL2A1-, and MMP13-positive cells based on staining results in (L) (n = 6 per group). Data are presented as mean ± SEM. Statistical significance was determined using ordinary one-way ANOVA.*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 RNF152 silencing alleviated TMJOA progression in model rats. A, Schematic of experimental design: TMJOA model rats were treated with intra-articular injections of RNF152-silencing AAV or control AAV vectors and evaluated at 16 weeks of age. B, In vivo imaging of rats at 1-month post-AAV injection. C, Spatial localization of the mandibular condyles of rat TMJs utilizing Imalytics Preclinical 3.1 software during micro-CT analysis. D-H, Analysis of BV/TV ratio, BS/BV ratio, Tb.Th, Tb.Sp, and BMD (n = 6 per group). I, Representative images of HE and Safranin O-fast green staining of the synovium and chondrocytes.Scale bars = 50 μm. J and K, Quantification of synovitis and OARSI grading systems based on staining results in (I) (n = 6 per group). L, Representative images of immunohistochemical staining for IL-6, COL2A1, and MMP13 in the synovium and chondrocytes.Scale bars = 20 μm. M-O, Quantification of IL-6–, COL2A1-, and MMP13-positive cells based on staining results in (L) (n = 6 per group). Data are presented as mean ± SEM. Statistical significance was determined using ordinary one-way ANOVA.*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 Based on our collective research findings, we propose a mechanism for TMJOA progression involving the RNF152/HSP27/PI3K/AKT axis (Fig. 8). Through this mechanism, RNF152 promotes activation of the PI3K/AKT pathway by targeting HSP27 for ubiquitin-mediated degradation, which then facilitates the progression of TMJOA (Fig. 8). Fig. 8Schematic representation of the effects of IL-1β–induced activation of FLSs by RNF152. IL-1β upregulates RNF152 expression in FLSs, leading to enhanced ubiquitination of HSP27, which promotes its proteasomal degradation. Sustained HSP27 depletion pathologically hyperactivates the PI3K/AKT signaling cascade, thereby accelerating transcription of downstream target genes, which ultimately drive FLS inflammatory responses and proliferative pathology Schematic representation of the effects of IL-1β–induced activation of FLSs by RNF152. IL-1β upregulates RNF152 expression in FLSs, leading to enhanced ubiquitination of HSP27, which promotes its proteasomal degradation. Sustained HSP27 depletion pathologically hyperactivates the PI3K/AKT signaling cascade, thereby accelerating transcription of downstream target genes, which ultimately drive FLS inflammatory responses and proliferative pathology Discussion While the primary symptoms of OA are derived from chondrocyte dysfunction, recent research has unequivocally established a critical role for synovial inflammation in OA pathogenesis [26]. Within the context of TMJOA, synovitis represents a pivotal pathological alteration. Under physiological conditions, synovium-derived lubricin and hyaluronic acid are essential for joint lubrication and the maintenance of cartilage homeostasis. However, inflammatory transformation of the synovium impairs its secretory capacity and compromises its barrier function, promoting articular wear and ultimately leading to cartilage degeneration [27]. IL-1β is currently recognized as the principal cytokine driving the amplification of the synovial inflammatory response and its transition towards destructive processes in TMJOA. IL-1β stimulates hyperplasia of synovial lining cells and induces the release of proinflammatory mediators (including cytokines, MMPs, nitric oxide, prostaglandin E2, and neuropeptides) into the synovial fluid. These mediators diffuse directly into the avascular articular cartilage, promoting its degradation [28–30]. Significantly, synovial inflammation is not merely a consequence of joint degeneration; instead, emerging evidence indicates its presence early in OA, when it may precede overt cartilage damage and act as a disease precursor. This is particularly evident in TMJOA, where synovitis persists throughout all disease stages and may be more pronounced in the early phases [31]. Consequently, the inflammatory cascade within the synovium, orchestrated by core mediators like IL-1β acting upon FLSs, constitutes a fundamental mechanism driving the initiation and progression of TMJOA. Therefore, we selected IL-1β as the stimulus in the present study to mimic the in vivo activated state of FLSs by inflammatory factors, enabling investigation into the specific molecular mechanisms underlying the pathogenesis of TMJOA. In recent years, ubiquitination has been established as a pivotal regulatory mechanism in several pathological processes, including OA [32]. Studies have demonstrated that members of the E3 ubiquitin ligase family, including neuronal precursor cell-expressed developmentally downregulated 4 (NEDD4), contribute to OA progression by modulating inflammation, autophagy, and other pathways [33]– [34]. Specific E3 ligases, such as HECT domain E3 ubiquitin protein ligase 1 (HECTD1), influence OA pathogenesis by degrading Rubicon to regulate autophagy [35]. Among the diverse E3 ubiquitin ligases, RNF152 is a structurally compact RING-type ligase. It features an N-terminal RING domain (catalytic domain) and a C-terminal hydrophobic transmembrane domain that mediates its lysosomal localization. Experimental evidence has confirmed that RNF152 possesses intrinsic E3 ligase activity, undergoing RING domain-dependent K48-linked auto-ubiquitination and subsequent degradation via the ubiquitin-proteasome pathway, implicating its role in proteostasis [36]. Although RNF152 has been characterized in various contexts such as cancer (exhibiting downregulation in breast, prostate, colorectal, lung, renal, and hepatocellular carcinomas) and metabolic regulation [37]– [38], its specific substrates and functions remain incompletely defined, and its role in TMJOA has not been reported. The present study is the first to investigate the function of RNF152 in TMJOA. Our data reveal that RNF152 expression is upregulated in IL-1β–stimulated FLSs. Critically, silencing of RNF152 effectively abolished the activated state of IL-1β–stimulated FLSs by suppressing their proliferation, inhibiting inflammatory mediator release, and promoting apoptosis. Furthermore, intra-articular injection of AAV-siRNF152 into the TMJ of UAC-induced TMJOA model rats significantly alleviated joint damage. These findings collectively indicate that targeting RNF152 represents a promising therapeutic strategy for TMJOA.It should be noted that the present study focused on the Synovial tissue. Future studies are warranted to investigate the potential role and expression pattern of RNF152 in other joint components, such as the TMJ disc, to gain a more comprehensive understanding of its function in TMJOA pathogenesis. To elucidate the molecular mechanism by which RNF152 contributes to the pathogenesis of TMJOA, we employed Co-IP coupled with MS to identify HSP27 as a potential target protein of RNF152. Our results demonstrated interaction between RNF152 and HSP27, with concomitant downregulation of HSP27 expression in IL-1β–stimulated FLSs. This observation aligns with prior evidence indicating HSP27 suppression in OA chondrocytes [14]. Functionally, HSP27 exerts anti-inflammatory effects through phosphorylation-dependent mechanisms. In a previous study, phosphorylated HSP27 was found to attenuate TNF-α, IL-1β, and IL-6 release by promoting TLR4 endocytosis and ubiquitin-mediated degradation, thereby inhibiting TLR4 signaling activation [24]. Furthermore, phosphorylated HSP27 was shown to modulate the transcriptional activity of NF-κB and activator protein 1 via regulation of CREB-binding protein (CBP) in THP-1 cells, playing a pivotal role in controlling LPS-induced inflammatory responses [39]. Notably, our functional validation confirmed the anti-inflammatory properties of HSP27 in TMJOA pathogenesis: overexpression of HSP27 significantly suppressed the IL-1β–induced proliferation and inflammatory cytokine production among FLSs. This study demonstrates that RNF152 overexpression exacerbates synovial inflammation in TMJOA by promoting HSP27 degradation, thereby activating the PI3K/AKT pathway. Notably, PI3K/AKT activation not only drives inflammation but also contributes to synovial hyperplasia by suppressing synoviocyte apoptosis and promoting proliferation/migration, as evidenced by the inhibition of cleaved caspase-3 and upregulation of Ki67 (a proliferation marker) in AKT downstream signaling[40].Furthermore, we observed that HSP27 degradation enhances PI3K/AKT activity—a finding that appears to contradict its previously reported cytoprotective roles in tissues such as myocardium[41]. This discrepancy may reflect fundamental differences between tissue-specific regulation and disease contexts: under acute injury conditions, HSP27 stabilizes Akt signaling to promote cell survival, whereas in chronic inflammatory states such as TMJOA, its persistent decrease leads to pathological overactivation of PI3K/AKT. Additionally, HSP27 may exert a concentration-dependent threshold effect, maintaining signaling homeostasis at physiological levels; once its expression drops below a critical threshold, it triggers pathway imbalance and amplifies inflammatory responses.Collectively, the RNF152/HSP27/PI3K/AKT axis reveals the unique role of RNF152 as an E3 ligase regulating chaperone stability in amplifying inflammation, and underscores the self-sustaining nature of chronic inflammation in TMJOA. Some limitations of the present study should be considered. This study employed human FLS models and a rat TMJOA model, and translational relevance may be limited by interspecies differences in TMJ anatomy, biomechanical loading, and immune responses between rodents and humans. Future validation of our findings in large-animal models (e.g., porcine) or humanized systems is warranted. Furthermore, the exclusive use of female SD rats in our experimental model represents a limitation, as it precludes us from accounting for the potential confounding protective effect of estrogen in TMJOA pathogenesis.Additionally, heterogeneity in synovial cell populations (e.g., FLSs vs. macrophage-like synoviocytes) and their differential responses to pathway activation remain unexplored, necessitating single-cell RNA-sequencing analyses for mechanistic characterization. Conclusions In conclusion, the present study delineated a pivotal pro-inflammatory axis involved in TMJOA progression: RNF152-mediated, ubiquitin-dependent degradation of HSP27 activates the PI3K/AKT pathway, driving synovial inflammatory cascades in TMJOA. This discovery expands our understanding of TMJOA pathogenesis and reveals a dual regulatory role of HSP27 in inflammatory signaling as well as the function of RNF152 as a novel E3 ligase, thereby identifying promising therapeutic targets for precise interventions in TMJOA. Supplementary Information Supplementary Material 1 Supplementary Material 1 Supplementary Material 2 Supplementary Material 2 Supplementary Material 3 Supplementary Material 3 Supplementary Material 4 Supplementary Material 4 Supplementary Material 5 Supplementary Material 5 Supplementary Material 6 Supplementary Material 6 Supplementary Material 7 Supplementary Material 7 Supplementary Material 8 Supplementary Material 8